Previous 10 | Next 10 |
Noteworthy events during the week of February 16 - 22 for healthcare investors. More news on: Agile Therapeutics, Inc., Merck & Co., Inc., Cellectar Biosciences, Inc., Healthcare stocks news, , Read more ...
LEXINGTON, Mass. , Feb. 6, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will hold an Investor Day Thursday, February 20, 2020 . The Investor D...
LEXINGTON, Mass. , Jan. 9, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment of Dr. Jennifer Buell to President and COO. "Jen's tenur...
LEXINGTON, Mass. , Jan. 8, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, announced the dosing of the first patient with AGEN1223. AGEN1223 is a novel bi-specific antibody discovere...
A home is not a mere transient shelter: its essence lies in the personalities of the people who live in it. ” - H.L. Mencken Today, we revisit a name I have fielded many inquiries around over the years. The company has some significant partnerships and a diverse pipeline with mul...
Dosing is underway in a Phase 1 dose-escalation study evaluating Agenus' (NASDAQ: AGEN ) AGEN1181 in patients with advanced solid tumors. More news on: Agenus Inc., Healthcare stocks news, Read more ...
LEXINGTON, Mass., Dec. 19, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 and cancer vaccines, today announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody,...
Introduction Through Week 49, the Premium Portfolio has gained +27.75%, beating the S&P 500 benchmark, while actively trading in 14 fewer weeks according to the Momentum Gauge timing signals. These returns represent better than 3 times the return of the Barclay Hedge Fund Index average r...
The healthcare sector seems to be waking up over the past several weeks. Political uncertainty has been hurting healthcare stocks throughout the past year, but this uncertainty seems to be dissipating as the Presidential election approaches, which is being a major tailwind for the healthcare ...
Agenus ( AGEN ) is one of the most exciting biotechnology companies available at a reasonable price today. After slumping to a 52-week low of $1.95 per share back in December 2018, news of a deal with Gilead ( GILD ) to license multiple potential cancer therapies pushed the stock back up in Ja...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...